<DOC>
	<DOCNO>NCT00068276</DOCNO>
	<brief_summary>RATIONALE : Cholecalciferol ( vitamin D ) may improve quality life increase blood count , decrease fatigue , improve symptom myelodysplastic syndrome . PURPOSE : This phase II trial study well cholecalciferol work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Cholecalciferol Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy cholecalciferol , term hematological improvement , patient low- intermediate-risk myelodysplastic syndrome . - Determine effect drug disease symptom , fatigue , overall health-related quality life patient . OUTLINE : This open-label , pilot study . Patients receive oral cholecalciferol daily . Treatment continue 6 month absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelodysplastic syndrome ( MDS ) Must undergone bone marrow aspirate biopsy karyotype within past 3 month International Prognostic Scoring System score 0 1 PATIENT CHARACTERISTICS : Age Any age Performance status Any Life expectancy More 1 year Hematopoietic Not specify Hepatic Not specify Renal No history hypercalcemia PRIOR CONCURRENT THERAPY : Biologic therapy Prior stem cell transplantation allow No concurrent hematopoietic growth factor Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 6 week since prior cholecalciferol supplement analogs More 4 week since prior therapy MDS ( except supportive care ) No concurrent therapy MDS</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>